Search research articles
Contact Us
Filters
Showing results (81-90 of 205) with videos related to
Page
of 21
Sort By:
Cardiovascular Clinics
|
January 1, 1985
Beta-adrenergic blockers in the prevention of sudden death
W H Frishman, L I Laifer, C D Furberg
The American Journal of Medicine
|
April 17, 1989
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group
C D Furberg, R P Byington, N A Borhani
Clinical Pharmacology and Therapeutics
|
June 1, 1987
Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial
B R Davis, C D Furberg, C B Williams
JAMA
|
May 30, 1998
Time to act on drug safety
T J Moore, B M Psaty, C D Furberg
Lancet (London, England)
|
October 8, 1999
Are drugs within a class interchangeable?
C D Furberg, D M Herrington, B M Psaty
Nederlands Tijdschrift Voor Geneeskunde
|
April 27, 1996
[Calcium antagonists: safe or unsafe?]
F R Rosendaal, B M Psaty, C D Furberg
Atherosclerosis
|
July 25, 1998
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
J R Crouse, R P Byington, C D Furberg
Stroke
|
April 1, 1988
Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review
G S Tell, J R Crouse, C D Furberg
Circulation
|
September 1, 1995
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
C D Furberg, B M Psaty, J V Meyer
The New England Journal of Medicine
|
March 29, 1984
Beta-adrenergic blockade for survivors of acute myocardial infarction
W H Frishman, C D Furberg, W T Friedewald
Page
of 21
Search research articles
Search
Showing results (81-90 of 205) with videos related to
Sort By:
Page
of 21
Cardiovascular Clinics
|
January 1, 1985
Beta-adrenergic blockers in the prevention of sudden death
W H Frishman, L I Laifer, C D Furberg
The American Journal of Medicine
|
April 17, 1989
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group
C D Furberg, R P Byington, N A Borhani
Clinical Pharmacology and Therapeutics
|
June 1, 1987
Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial
B R Davis, C D Furberg, C B Williams
JAMA
|
May 30, 1998
Time to act on drug safety
T J Moore, B M Psaty, C D Furberg
Lancet (London, England)
|
October 8, 1999
Are drugs within a class interchangeable?
C D Furberg, D M Herrington, B M Psaty
Nederlands Tijdschrift Voor Geneeskunde
|
April 27, 1996
[Calcium antagonists: safe or unsafe?]
F R Rosendaal, B M Psaty, C D Furberg
Atherosclerosis
|
July 25, 1998
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
J R Crouse, R P Byington, C D Furberg
Stroke
|
April 1, 1988
Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review
G S Tell, J R Crouse, C D Furberg
Circulation
|
September 1, 1995
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
C D Furberg, B M Psaty, J V Meyer
The New England Journal of Medicine
|
March 29, 1984
Beta-adrenergic blockade for survivors of acute myocardial infarction
W H Frishman, C D Furberg, W T Friedewald
Page
of 21